Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
3 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Maze Therapeutics, Inc.’s names, not what it holds today.
Patents granted
3
3 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and 1 in 2023
Applications published
11
3 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Maze Therapeutics, Inc. its own name
named as the applicant on its applications, in US
11 publishedMaze Therapeutics, Inc. its own name
US, as the owner printed on each patent
0 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Jul 1, 2025 | 12,344,610 | APOL1 inhibitors and methods of use | Organic fine chemistry | Maze Therapeutics, Inc. |
| May 7, 2024 | 11,976,067 | APOL1 inhibitors and methods of use | Organic fine chemistry | Maze Therapeutics, Inc. |
| Nov 14, 2023 | 11,814,367 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | Organic fine chemistry | Maze Therapeutics, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Oct 16, 2025 | 2025/0320196 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | Organic fine chemistry | Maze Therapeutics, Inc. |
| Sep 11, 2025 | 2025/0282781 | APOL1 INHIBITORS AND METHODS OF USE | Organic fine chemistry | Maze Therapeutics, Inc. |
| Jan 9, 2025 | 2025/0011773 | COMPOSITIONS AND METHODS FOR TREATING TDP-43 PROTEINOPATHY | Biotechnology | Maze Therapeutics, Inc. |
| Dec 5, 2024 | 2024/0400565 | APOL1 INHIBITORS AND METHODS OF USE | Organic fine chemistry | Maze Therapeutics, Inc. · patent 12,344,610 granted from it |
| Sep 26, 2024 | 2024/0316038 | APOL1 INHIBITORS AND METHODS OF USE | Organic fine chemistry | Maze Therapeutics, Inc. |
| Jul 25, 2024 | 2024/0246939 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | Organic fine chemistry | Maze Therapeutics, Inc. |
| Jun 20, 2024 | 2024/0199546 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | Organic fine chemistry | Maze Therapeutics, Inc. |
| Mar 21, 2024 | 2024/0093189 | VECTORS COMPRISING STUFFER POLYNUCLEOTIDE SEQUENCES | Biotechnology | Maze Therapeutics, Inc. |
| Sep 14, 2023 | 2023/0287409 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | Biotechnology | Maze Therapeutics, Inc. |
| Aug 24, 2023 | 2023/0265096 | APOL1 INHIBITORS AND METHODS OF USE | Organic fine chemistry | Maze Therapeutics, Inc. · patent 11,976,067 granted from it |
What it applied for, 2024 to 2025: Organic fine chemistry 6 · Biotechnology 2.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.